1. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Issue 5 (May 2019) Authors: Bashir, Qaiser; Thall, Peter F; Milton, Denái R; Fox, Patricia S; Kawedia, Jitesh D; Kebriaei, Partow; Shah, Nina; Patel, Krina; Andersson, Borje S; Nieto, Yago L; Valdez, Ben C; Parmar, Simrit; Rondon, Gabriela; Delgado, Ruby; Hosing, Chitra; Popat, Uday R; Oran, Betul; Ciurea, Stefan O; Lin, Pe... Journal: Lancet Issue: Volume 6:Issue 5(2019) Page Start: e266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Issue 11 (November 2018) Authors: Popat, Uday R; Mehta, Rohtesh S; Bassett, Roland; Chen, Julianne; Valdez, Benigno C; Kawedia, Jitesh; Ahmed, Sairah; Alousi, Amin M; Anderlini, Paolo; Al-Atrash, Geath; Bashir, Qaiser; Ciurea, Stefan O; Hosing, Chitra M; Im, Jin S; Jones, Roy; Kebriaei, Partow; Khouri, Issa; Marin, David; Nieto, ... Journal: Lancet Issue: Volume 5:Issue 11(2018) Page Start: e532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Issue 6 (June 2017) Authors: Nieto, Yago; Valdez, Benigno C; Pingali, Sai R; Bassett, Roland; Delgado, Ruby; Nguyen, John; Shah, Nina; Popat, Uday; Jones, Roy B; Andersson, Borje S; Gulbis, Alison; Ahmed, Sairah; Bashir, Qaiser; Parmar, Simrit; Patel, Krina; Myers, Alan; Rondon, Gabriela; Orlowski, Robert Z; Champlin, Richar... Journal: Lancet Issue: Volume 4:Issue 6(2017) Page Start: e283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. (January 2013) Authors: Hassan, Moustapha; Andersson, Borje S Journal: Pharmacogenomics Issue: Volume 14:Number 1(2013) Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. (January 2013) Authors: Hassan, Moustapha; Andersson, Borje S Journal: Pharmacogenomics Issue: Volume 14:Number 1(2013) Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗